Medite Cancer Diagnostics Inc MDIT Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Jul 27, 2018 (filed on Jul 30, 2018)

Insider Name:

Von Rump Stephen L.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

133,333

Price:

$0.08
Jul 25, 2018 (filed on Jul 30, 2018)

Insider Name:

Lewis William Austin IV

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

1,100,000

Price:

$0.08
Jul 20, 2018 (filed on Jul 20, 2018)

Insider Name:

Von Rump Stephen L.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Jul 09, 2018 (filed on Jul 12, 2018)

Insider Name:

Lewis William Austin IV

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

400,000

Price:

$0.08
Jul 09, 2018 (filed on Jul 12, 2018)

Insider Name:

Lewis William Austin IV

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

6,933,333

Price:

$0.08
Jul 03, 2018 (filed on Jul 10, 2018)

Insider Name:

Abeles John H

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

400,000

Price:

$0.08
Jun 28, 2018 (filed on Jul 05, 2018)

Insider Name:

Lewis William Austin IV

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

1,333,334

Price:

$0.08
May 08, 2018 (filed on May 08, 2018)

Insider Name:

Fortunoff Gregory

Ownership Type:

Direct Ownership

Securities:

Warrant

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
May 08, 2018 (filed on May 08, 2018)

Insider Name:

Fortunoff Gregory

Ownership Type:

Direct Ownership

Securities:

Secured Convertible Note

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
May 08, 2018 (filed on May 08, 2018)

Insider Name:

Fortunoff Gregory

Ownership Type:

Direct Ownership

Securities:

Warrant

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--

Filings by filing date

Jul 25, 2018 (filed on Jul 30, 2018)

Insider Name:

Lewis William Austin IV

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

1,100,000

Price:

$0.08
Jul 27, 2018 (filed on Jul 30, 2018)

Insider Name:

Von Rump Stephen L.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

133,333

Price:

$0.08
Jul 20, 2018 (filed on Jul 20, 2018)

Insider Name:

Von Rump Stephen L.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Jul 09, 2018 (filed on Jul 12, 2018)

Insider Name:

Lewis William Austin IV

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

400,000

Price:

$0.08
Jul 09, 2018 (filed on Jul 12, 2018)

Insider Name:

Lewis William Austin IV

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

6,933,333

Price:

$0.08
Jul 03, 2018 (filed on Jul 10, 2018)

Insider Name:

Abeles John H

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

400,000

Price:

$0.08
Jun 28, 2018 (filed on Jul 05, 2018)

Insider Name:

Lewis William Austin IV

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

1,333,334

Price:

$0.08
Apr 26, 2018 (filed on Jul 05, 2018)

Insider Name:

Lewis William Austin IV

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

8,000,000

Price:

$0.08
Feb 04, 2018 (filed on May 08, 2018)

Insider Name:

Fortunoff Gregory

Ownership Type:

Direct Ownership

Securities:

Secured Convertible Note

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

100,000

Price:

$0.08
Apr 04, 2018 (filed on May 08, 2018)

Insider Name:

Fortunoff Gregory

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

1,333,334

Price:

$0.75

News

Biz Brief

Sector: Healthcare	Industry: Advanced Medical Equipment & Technology

See Regulatory Filings on SEC

Company Contact

Address:	414 N Orleans St Ste 502 CHICAGO IL 60654-4498
Tel:	N/A
Website:	https://www.medite-group.com
IR:	See website

Key People

W. Austin Lewis Chairman of the Board	Stephen L. Von Rump Chief Executive Officer, Interim Chief Financial Officer, Director	Michaela Ott Chief Operating Officer
Jeff Rencher Chief Marketing and Business Development Officer

Business Overview

MEDITE Cancer Diagnostics, Inc. (MEDITE), formerly CytoCore, Inc., is a medical technology company engaged in the development, engineering, manufacturing and marketing of molecular biomarkers and medical devices and consumables for detection, risk assessment and diagnosis of cancer, precancerous conditions and related diseases. The Company develops, manufactures and sells a range of laboratory devices and consumable supplies for its target market in the histology and cytology cancer diagnostics segment. The Company offers a range of histology laboratory devices for processing tissue, from receiving the tissue in the laboratory to the final diagnosis. The Company offers USE33, an ultrasonic decalcification instrument that runs the process under controlled temperatures. The Company also offers TPC15 Duo or Trio, TES99, TES Valida, M530, A550, M380, TST44 and COT20 linear staining systems. In addition, the Company also offers RCM9000, ACS720 and TWISTER glass and robotic coverslippers.

Financial Overview

For the three months ended 31 March 2018, Medite Cancer Diagnostics Inc revenues decreased 20% to $1.5M. Net loss applicable to common stockholders increased 46% to $1.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Interest expense increase from $193K to $447K (expense), Selling increase of 18% to $919K (expense).

Employees:	5 as of Mar 27, 2014

Reporting Currency:	U.S. Dollars
Enterprise value:	$9.76M as of Jun 30, 2018
Annual revenue (TTM):	$6.43M as of Jun 30, 2018
EBITDA (TTM):	-$6.55M as of Jun 30, 2018
Net annual income (TTM):	-$7.35M as of Jun 30, 2018
Free cash flow (TTM):	-$4.69M as of Jun 30, 2018
Net Debt Last Fiscal Year:	$5.05M as of Jun 30, 2018
Shares outstanding:	73,506,201 as of Aug 10, 2018
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization